. Author manuscript; available in PMC: 2021 May 31.

Published in final edited form as: Cancer Prev Res (Phila). 2019 Nov 26;13(1):91–100. doi: 10.1158/1940-6207.CAPR-19-0296

Table 4.

Effects of GST genotype on urinary MHBMA and DHBMA concentrations at week two baseline.

GST genotype	N	Geometric mean (95% CI)
GST genotype	N	MHBMA (ng/mg Cr)^a	DHBMA (ng/mg Cr)^a
*GSTT1*
Null	18	7.8 (4.9, 12.5)	891.3 (568.8, 1396.8)
Present	61	17.1 (13.3, 22.0)	645.9 (507.5, 822.1)
% Difference		219.5 (28.3, 375.6)	72.5 (−56.6, 21.1)
P-value^b		0.01	0.22
*GSTM1*
Null	36	15.1 (10.7, 21.5)	803.4 (584.3, 1104.5)
Present	43	13.6 (9.9, 18.7)	615.8 (460.6, 823.3)
% Difference		90.0 (−44.4, 45.5)	76.7 (−50.5, 18.8)
P-value^b		0.67	0.24

Urinary biomarkers were adjusted for creatinine and batch, and log-transformed.

Two-sided p-values were from linear regression models that test the GST genotype effect on week 2 baseline values, after adjusting for creatinine-adjusted TNE.